Journal
JOURNAL OF CARDIOLOGY
Volume 77, Issue 6, Pages 652-659Publisher
ELSEVIER
DOI: 10.1016/j.jjcc.2020.12.010
Keywords
Atrial fibrillation; Catheter ablation; Dabigatran; Integrated analysis
Categories
Ask authors/readers for more resources
An integrated analysis of the RE-CIRCUIT and ABRIDGE-J trials showed that an oral administration to ablation time of 8-24 hours for dabigatran during catheter ablation for atrial fibrillation was associated with fewer bleeding complications. This suggests that a dabigatran interruption time of 8-24 hours may be a suitable option, especially for low thromboembolic-risk patients.
Background: RE-CIRCUIT (NCT02348723) and ABRIDGE-J (UMIN0 0 0 013129) are recently published randomized clinical trials showing that anticoagulation therapy with dabigatran during the periprocedural period of catheter ablation (CA) for atrial fibrillation (AF) was associated with fewer complications. However, the dabigatran administration protocols were different (uninterrupted in RE-CIRCUIT and minimally interrupted in ABRIDGE-J). The aim of this present study was to clarify the optimal interruption time of dabigatran Oral administration to Ablation (O-A time). Methods: We conducted an integrated analysis of the 2 prospective trials. The endpoint of the study was the incidence of major bleeding events during and up to 8 weeks after CA across participants with different O-A times. Results: The 535 patients in the dabigatran groups of the 2 trials were divided into 3 groups based on their O-A times ( 8 h, n = 258; 8?24 h, n = 191; 8 h group, and 3 (3.5%) in the 24 h group; however, no major bleeding events occurred in the 8?24 h group (3 group-comparison, p = 0.026). No thromboembolic complication was observed in any of the 3 O-A time groups. Conclusion: In patients undergoing CA for AF using dabigatran as a periprocedural anticoagulant, an O-A time of 8?24 h was associated with no bleeding complications. These data suggest that an O-A time of 8?24 h may be an appropriate option, especially in a low thromboembolic-risk patient. ? 2021 The Authors. Published by Elsevier Ltd on behalf of Japanese College of Cardiology. This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ )
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available